Cancer Research 09 AM Call for Abstracts  SU2C
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nagorsen, D.
Right arrow Articles by Scheibenbogen, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nagorsen, D.
Right arrow Articles by Scheibenbogen, C.
[Cancer Research 60, 4850-4854, September 1, 2000]
© 2000 American Association for Cancer Research


Immunology

Natural T-cell Response against MHC Class I Epitopes of Epithelial Cell Adhesion Molecule, her-2/neu, and Carcinoembryonic Antigen in Patients with Colorectal Cancer1

Dirk Nagorsen, Ulrich Keilholz, Licia Rivoltini, Alexander Schmittel, Anne Letsch, Anne Marie Asemissen, Gerd Berger, Heinz-Johannes Buhr, Eckhard Thiel and Carmen Scheibenbogen2

Medizinische Klinik III, Hematology, Oncology and Transfusion Medicine [D. N., U. K., A. S., A. L., A. M. A., E. T., C. S.] and Chirurgische Klinik, Surgery [G. B., H-J. B.], University Hospital Benjamin Franklin, Free University Berlin, 12200 Berlin, Germany, and Istituto Nazionale Tumori, 20133 Milan, Italy [L. R.]

The antigens epithelial cell adhesion molecule (Ep-CAM), her-2/neu, and carcinoembryonic antigen (CEA) are potential T-cell targets in antigen-specific vaccination-based cancer therapy. We performed this study to evaluate whether a natural specific T-cell response against these tumor-associated antigens (TAAs) already exists in patients with colorectal carcinoma (CRC). We used the IFN-{gamma} ELISPOT assay to detect circulating TAA-reactive T cells directly ex vivo in unstimulated peripheral blood mononuclear cells. We analyzed the T-cell response in peripheral blood mononuclear cells of 22 HLA-A2-positive patients with CRC and 8 HLA-A2-positive healthy subjects against 3 HLA A2-restricted peptide epitopes of the TAAs Ep-CAM (GLKAGVIAV), her-2/neu (IISAVVGIL), and CEA (YLSGANLNL). Seven of 22 patients but none of the 8 healthy subjects had T cells specifically secreting IFN-{gamma} in response to one to three of these antigens (n = 4, Ep-CAM; n = 5, her-2/neu; n = 6, CEA). In three of the seven responding patients, TAA-reactive T cells were further characterized by flow cytometry. In all three patients, the majority of these T cells have a CD3+CD8+IFN-{gamma}+CD69+CD45RA+ phenotype, resembling activated effector-type T cells. T-cell responses occurred only in patients with metastatic disease (Dukes’ stages C and D). The results of this study indicate that natural T-cell responses against TAAs occur in approximately one-half of CRC patients with involvement of lymph nodes or distant metastases, but not in CRC patients with disease confined to the intestinum.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
C. Maccalli, V. Di Cristanziano, V. Fodale, D. Corsi, G. D'Agostino, V. Petrangeli, L. Laurenti, S. Guida, A. Mazzocchi, F. Arienti, et al.
Induction of Both CD8+ and CD4+ T-Cell-Mediated Responses in Colorectal Cancer Patients by Colon Antigen-1
Clin. Cancer Res., November 15, 2008; 14(22): 7292 - 7303.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. Parmiani, V. Russo, A. Marrari, G. Cutolo, C. Casati, L. Pilla, C. Maccalli, L. Rivoltini, and C. Castelli
Universal and Stemness-Related Tumor Antigens: Potential Use in Cancer Immunotherapy
Clin. Cancer Res., October 1, 2007; 13(19): 5675 - 5679.
[Full Text] [PDF]


Home page
JCOHome page
J. W. Park, M. E. Melisko, L. J. Esserman, L. A. Jones, J. B. Wollan, and R. Sims
Treatment With Autologous Antigen-Presenting Cells Activated With the HER-2 Based Antigen Lapuleucel-T: Results of a Phase I Study in Immunologic and Clinical Activity in HER-2 Overexpressing Breast Cancer
J. Clin. Oncol., August 20, 2007; 25(24): 3680 - 3687.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Inokuma, C. dela Rosa, C. Schmitt, P. Haaland, J. Siebert, D. Petry, M. Tang, M. A. Suni, S. A. Ghanekar, D. Gladding, et al.
Functional T Cell Responses to Tumor Antigens in Breast Cancer Patients Have a Distinct Phenotype and Cytokine Signature
J. Immunol., August 15, 2007; 179(4): 2627 - 2633.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
W. J. Lesterhuis, I. J. M. de Vries, D. H. Schuurhuis, A. C. I. Boullart, J. F. M. Jacobs, A. J. de Boer, N. M. Scharenborg, H. M. H. Brouwer, M. W. M. M. van de Rakt, C. G. Figdor, et al.
Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests
Ann. Onc., June 1, 2006; 17(6): 974 - 980.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. Nagorsen and E. Thiel
Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer.
Clin. Cancer Res., May 15, 2006; 12(10): 3064 - 3069.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Di Pucchio, L. Pilla, I. Capone, M. Ferrantini, E. Montefiore, F. Urbani, R. Patuzzo, E. Pennacchioli, M. Santinami, A. Cova, et al.
Immunization of Stage IV Melanoma Patients with Melan-A/MART-1 and gp100 Peptides plus IFN-{alpha} Results in the Activation of Specific CD8+ T Cells and Monocyte/Dendritic Cell Precursors.
Cancer Res., May 1, 2006; 66(9): 4943 - 4951.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
U. Keilholz, P. Martus, and C. Scheibenbogen
Immune monitoring of T-cell responses in cancer vaccine development.
Clin. Cancer Res., April 1, 2006; 12(7): 2346s - 2352s.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
B. Kubuschok, F. Neumann, R. Breit, M. Sester, C. Schormann, C. Wagner, U. Sester, F. Hartmann, M. Wagner, K. Remberger, et al.
Naturally Occurring T-Cell Response against Mutated p21 Ras Oncoprotein in Pancreatic Cancer
Clin. Cancer Res., February 15, 2006; 12(4): 1365 - 1372.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. R. Weihrauch, S. Ansen, E. Jurkiewicz, C. Geisen, Z. Xia, K. S. Anderson, E. Gracien, M. Schmidt, B. Wittig, V. Diehl, et al.
Phase I/II Combined Chemoimmunotherapy with Carcinoembryonic Antigen-Derived HLA-A2-Restricted CAP-1 Peptide and Irinotecan, 5-Fluorouracil, and Leucovorin in Patients with Primary Metastatic Colorectal Cancer
Clin. Cancer Res., August 15, 2005; 11(16): 5993 - 6001.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Machlenkin, A. Paz, E. Bar Haim, O. Goldberger, E. Finkel, B. Tirosh, I. Volovitz, E. Vadai, G. Lugassy, S. Cytron, et al.
Human CTL Epitopes Prostatic Acid Phosphatase-3 and Six-Transmembrane Epithelial Antigen of Prostate-3 as Candidates for Prostate Cancer Immunotherapy
Cancer Res., July 15, 2005; 65(14): 6435 - 6442.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. P.J.M. van Gisbergen, C. A. Aarnoudse, G. A. Meijer, T. B.H. Geijtenbeek, and Y. van Kooyk
Dendritic Cells Recognize Tumor-Specific Glycosylation of Carcinoembryonic Antigen on Colorectal Cancer Cells through Dendritic Cell-Specific Intercellular Adhesion Molecule-3-Grabbing Nonintegrin
Cancer Res., July 1, 2005; 65(13): 5935 - 5944.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
S. Mosolits, G. Ullenhag, and H. Mellstedt
Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results
Ann. Onc., June 1, 2005; 16(6): 847 - 862.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
O. Schmetzer, G. Moldenhauer, R. Riesenberg, J. R. Pires, P. Schlag, and A. Pezzutto
Quality of Recombinant Protein Determines the Amount of Autoreactivity Detected against the Tumor-Associated Epithelial Cell Adhesion Molecule Antigen: Low Frequency of Antibodies against the Natural Protein
J. Immunol., January 15, 2005; 174(2): 942 - 952.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Mosolits, K. Markovic, J.-E. Frodin, L. Virving, C. G. M. Magnusson, M. Steinitz, J. Fagerberg, and H. Mellstedt
Vaccination with Ep-CAM Protein or Anti-Idiotypic Antibody Induces Th1-Biased Response against MHC Class I- and II-Restricted Ep-CAM Epitopes in Colorectal Carcinoma Patients
Clin. Cancer Res., August 15, 2004; 10(16): 5391 - 5402.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. Rivoltini, C. Castelli, M. Carrabba, V. Mazzaferro, L. Pilla, V. Huber, J. Coppa, G. Gallino, C. Scheibenbogen, P. Squarcina, et al.
Human Tumor-Derived Heat Shock Protein 96 Mediates In Vitro Activation and In Vivo Expansion of Melanoma- and Colon Carcinoma-Specific T Cells
J. Immunol., October 1, 2003; 171(7): 3467 - 3474.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. Nagorsen, C. Scheibenbogen, F. M. Marincola, A. Letsch, and U. Keilholz
Natural T Cell Immunity against Cancer
Clin. Cancer Res., October 1, 2003; 9(12): 4296 - 4303.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Casati, P. Dalerba, L. Rivoltini, G. Gallino, P. Deho, F. Rini, F. Belli, D. Mezzanzanica, A. Costa, S. Andreola, et al.
The Apoptosis Inhibitor Protein Survivin Induces Tumor-specific CD8+ and CD4+ T Cells in Colorectal Cancer Patients
Cancer Res., August 1, 2003; 63(15): 4507 - 4515.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
V. Mazzaferro, J. Coppa, M. G. Carrabba, L. Rivoltini, M. Schiavo, E. Regalia, L. Mariani, T. Camerini, A. Marchiano, S. Andreola, et al.
Vaccination with Autologous Tumor-derived Heat-Shock Protein Gp96 after Liver Resection for Metastatic Colorectal Cancer
Clin. Cancer Res., August 1, 2003; 9(9): 3235 - 3245.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. J. Ullenhag, J.-E. Frodin, S. Mosolits, S. Kiaii, M. Hassan, M. C. Bonnet, P. Moingeon, H. Mellstedt, and H. Rabbani
Immunization of Colorectal Carcinoma Patients with a Recombinant Canarypox Virus Expressing the Tumor Antigen Ep-CAM/KSA (ALVAC-KSA) and Granulocyte Macrophage Colony- stimulating Factor Induced a Tumor-specific Cellular Immune Response
Clin. Cancer Res., July 1, 2003; 9(7): 2447 - 2456.
[Abstract] [Full Text] [PDF]


Home page
Br Med BullHome page
C. L Smith, N. Dulphy, M. Salio, and V. Cerundolo
Immunotherapy of colorectal cancer
Br. Med. Bull., December 1, 2002; 64(1): 181 - 200.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
F. Belli, A. Testori, L. Rivoltini, M. Maio, G. Andreola, M. R. Sertoli, G. Gallino, A. Piris, A. Cattelan, I. Lazzari, et al.
Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings
J. Clin. Oncol., October 15, 2002; 20(20): 4169 - 4180.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
G. Parmiani, C. Castelli, P. Dalerba, R. Mortarini, L. Rivoltini, F. M. Marincola, and A. Anichini
Cancer Immunotherapy With Peptide-Based Vaccines: What Have We Achieved? Where Are We Going?
J Natl Cancer Inst, June 5, 2002; 94(11): 805 - 818.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Horig, A. Wainstein, L. Long, D. Kahn, S. Soni, A. Marcus, W. Edelmann, R. Kucherlapati, and H. L. Kaufman
A New Mouse Model for Evaluating the Immunotherapy of Human Colorectal Cancer
Cancer Res., December 1, 2001; 61(23): 8520 - 8526.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Trojan, M. Witzens, J. L. Schultze, R. H. Vonderheide, S. Harig, A. M. Krackhardt, R. A. Stahel, and J. G. Gribben
Generation of Cytotoxic T Lymphocytes against Native and Altered Peptides of Human Leukocyte Antigen-A*0201 Restricted Epitopes from the Human Epithelial Cell Adhesion Molecule
Cancer Res., June 1, 2001; 61(12): 4761 - 4765.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.